The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer.
Sarah McCuaigDavid BarrasElizabeth H MannMatthias FriedrichSamuel J BullersAlina JanneyLucy C GarnerEnric DomingoViktor Hendrik KoelzerMauro DelorenziSabine TejparTimothy S MaughanNathaniel R WestFiona PowriePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Interactions between KRAS and IL22 signaling may underlie a previously unrecognized subset of clinically aggressive colorectal cancer that could benefit from therapeutic modulation of the IL22 pathway.